Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis of whether an antagonist at the corticotropin releasing
factor type 1 (CRF1) receptor (i.e. GSK561679) is superior to placebo in reducing symptoms of
post-traumatic stress disorder (PTSD).